AIM ImmunoTech signs manufacturing deal, ends ATM stock sale program

AIM ImmunoTech Inc. entered into a new manufacturing proposal with Sterling Pharma Solutions on July 31, 2026, building on a Master Service Agreement and Quality Agreement the two parties signed in 2022. Under the proposal, Sterling agreed to manufacture further batches of the polynucleotide drug substances PolyI and Poly C12U and to transfer associated test methods at its Dudley, UK facility to produce the polymer precursors used to make the drug Ampligen.¹

AIM estimated the cost of the agreement at approximately $1.5 million, to be paid over 12 months.¹ The company said it plans to use the manufactured product for ongoing and future clinical trials, including a possible Phase 3 trial in metastatic pancreatic cancer.¹

On the same day, AIM also moved to end its at-the-market stock sale arrangement. The company had been party to an Equity Distribution Agreement with Maxim Group LLC, dated April 1, 2025 and amended April 10, 2026, allowing sales of common stock under Rule 415.² On July 31, 2026, AIM notified Maxim of a mutual termination of the agreement, effective August 15, 2026.² The company said it will not incur any termination penalties.²

Between April 1, 2025 and July 31, 2026, AIM sold 3,200,736 shares under the agreement for aggregate gross proceeds of approximately $2.8 million.² The company said it does not intend to sell additional shares under the agreement before termination.²

Separately, AIM disclosed shareholder nomination deadlines for its 2026 annual meeting. Stockholder director nominations or other proposals not covered by Rule 14a-8 must be received between August 18 and September 17, 2026.¹ Stockholders seeking to solicit proxies for alternative nominees under universal proxy rules must submit required information by October 19, 2026.¹